CHANNEL THERAPEUTICS CORP (CHRO) Stock Overview
NYSEARCA:CHRO - US1711261057 - Common Stock
CHRO Key Statistics, Chart & Performance
The current stock price of CHRO is 1.35 USD. In the past month the price increased by 32.35%. In the past year, price increased by 9.76%.
CHRO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.63 | 367.30B | ||
| AMGN | AMGEN INC | 13.1 | 153.76B | ||
| GILD | GILEAD SCIENCES INC | 14.54 | 139.67B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.14 | 100.52B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.7 | 61.43B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.29B | ||
| ARGX | ARGENX SE - ADR | 75.95 | 43.09B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.02 | 35.42B | ||
| INSM | INSMED INC | N/A | 28.53B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.50B | ||
| NTRA | NATERA INC | N/A | 23.04B | ||
| BIIB | BIOGEN INC | 8.29 | 19.45B |
Related stock screener links
About CHRO
Company Profile
Chromocell Therapeutics Corp. is a clinical-stage biotech company that engages in the development and commercialization of new therapeutics to alleviate pain. The company is headquartered in North Brunswick, New Jersey and currently employs 4 full-time employees. The firm's clinical focus is to selectively target the sodium ion-channel, NaV1.7, as well as other receptors in the NaV family. Its lead compound, CC8464, is designed to address both the underlying condition and mitigate the burning pain symptoms, which erythromelalgia (EM) patients experience by blocking the NaV1.7 sodium channel. CC8464 has completed Phase I study. A total of approximately 207 healthy subjects have been dosed in four Phase I studies (CC8464-1001, CC8464-1002, CC8464-1003, and 1807-CL-0102) with study treatment.
Company Info
CHANNEL THERAPEUTICS CORP
685 US Highway One
North Brunswick NEW JERSEY US
Employees: 4
Phone: 19176446313
CHANNEL THERAPEUTICS CORP / CHRO FAQ
What is the stock price of CHANNEL THERAPEUTICS CORP today?
The current stock price of CHRO is 1.35 USD. The price increased by 7.14% in the last trading session.
What is the ticker symbol for CHANNEL THERAPEUTICS CORP stock?
The exchange symbol of CHANNEL THERAPEUTICS CORP is CHRO and it is listed on the NYSE Arca exchange.
On which exchange is CHRO stock listed?
CHRO stock is listed on the NYSE Arca exchange.
What is CHANNEL THERAPEUTICS CORP worth?
CHANNEL THERAPEUTICS CORP (CHRO) has a market capitalization of 8.14M USD. This makes CHRO a Nano Cap stock.
How many employees does CHANNEL THERAPEUTICS CORP have?
CHANNEL THERAPEUTICS CORP (CHRO) currently has 4 employees.
What are the support and resistance levels for CHANNEL THERAPEUTICS CORP (CHRO) stock?
CHANNEL THERAPEUTICS CORP (CHRO) has a support level at 1 and a resistance level at 1.36. Check the full technical report for a detailed analysis of CHRO support and resistance levels.
Should I buy CHANNEL THERAPEUTICS CORP (CHRO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CHRO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CHRO, evaluating the profitability, health, valuation and growth aspects
- CHANNEL THERAPEUTICS CORP (CHRO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CHANNEL THERAPEUTICS CORP (CHRO) Sales and EPS estimates to see what analysts future expectations are.
- CHANNEL THERAPEUTICS CORP (CHRO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CHANNEL THERAPEUTICS CORP (CHRO) Insider and Institutional Ownership to learn about the owners and their transactions.
- CHANNEL THERAPEUTICS CORP (CHRO) Stock Chart to make your own analysis
- CHANNEL THERAPEUTICS CORP (CHRO) Latest news and press-releases to stay up to date.
Does CHANNEL THERAPEUTICS CORP (CHRO) stock pay dividends?
CHRO does not pay a dividend.
What is the Price/Earnings (PE) ratio of CHANNEL THERAPEUTICS CORP (CHRO)?
CHANNEL THERAPEUTICS CORP (CHRO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.28).
CHRO Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to CHRO. When comparing the yearly performance of all stocks, CHRO turns out to be only a medium performer in the overall market: it outperformed 42.86% of all stocks.
CHRO Financial Highlights
Over the last trailing twelve months CHRO reported a non-GAAP Earnings per Share(EPS) of -1.28. The EPS decreased by -197.6% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -810.01% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |